Cyclodiode laser is an effective alternative to lensectomy in acute angle closure

Article

Using a cyclodiode laser to manage acute angle closure is a safe and effective alternative to emergency lensectomy or trabeculectomy

Using a cyclodiode laser to manage acute angle closure is a safe and effective alternative to emergency lensectomy or trabeculectomy, claims a study in the journal Eye.

Dr A. Manna et al., Birmingham Midland Eye Centre, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK, conducted a retrospective case series on five patients with acute angle closure refractory to medical and laser treatment.

All participants underwent cyclodiode laser treatment. The team recorded each patient's demographic information, symptoms, medical and surgical treatment, visual outcomes and intraocular pressure (IOP).

Sufficient IOP control was not achieved with conventional management such as topical and systemic medical treatment, laser iridotomy and laser iridoplasty. Within 2 to 23 days of presentation of acute angle closure, emergency cyclodiode laser treatment was completed.

Lensectomy was performed in all patients at a later date, with final visual acuity of 6/12 or better with well-maintained IOPs. Just one patient required topical treatment and one patient developed persistent low-grade anterior uveitis.

Cyclodiode laser treatment is a successful alternative to managing acute angle closure for patients who do not respond to other treatments.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.